What is a stock summary page? Click here for an overview.
Business Description
Cardiff Oncology Inc
NAICS : 325414
SIC : 2836
ISIN : US8972384080
Compare
Compare
Traded in other countries / regions
CRDF.USAXE7C.Germany Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
1997-05-22Description
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 60.24 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 1.65 | |||||
| Beneish M-Score | -2.01 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.9 | |||||
| 3-Year EBITDA Growth Rate | -11.6 | |||||
| 3-Year EPS without NRI Growth Rate | -8.8 | |||||
| 3-Year FCF Growth Rate | -10 | |||||
| 3-Year Book Growth Rate | -28 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -10.72 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -42.7 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 5.81 | |||||
| 9-Day RSI | 18.46 | |||||
| 14-Day RSI | 28.12 | |||||
| 3-1 Month Momentum % | -20.53 | |||||
| 6-1 Month Momentum % | 43.65 | |||||
| 12-1 Month Momentum % | -34.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.08 | |||||
| Quick Ratio | 7.08 | |||||
| Cash Ratio | 6.83 | |||||
| Days Sales Outstanding | 269.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.6 | |||||
| Shareholder Yield % | -28.86 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -7112.72 | |||||
| Net Margin % | -6641.96 | |||||
| FCF Margin % | -5522.37 | |||||
| ROE % | -72.03 | |||||
| ROA % | -59.49 | |||||
| ROIC % | -765.34 | |||||
| 3-Year ROIIC % | -13466.67 | |||||
| ROC (Joel Greenblatt) % | -1927.99 | |||||
| ROCE % | -75.77 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 171.88 | |||||
| PB Ratio | 2.21 | |||||
| Price-to-Tangible-Book | 2.21 | |||||
| EV-to-EBIT | -1.91 | |||||
| EV-to-EBITDA | -1.92 | |||||
| EV-to-Revenue | 135.55 | |||||
| EV-to-Forward-Revenue | 132.46 | |||||
| EV-to-FCF | -2.45 | |||||
| Price-to-GF-Value | 0.91 | |||||
| Price-to-Median-PS-Value | 0.96 | |||||
| Price-to-Net-Current-Asset-Value | 2.27 | |||||
| Price-to-Net-Cash | 2.35 | |||||
| Earnings Yield (Greenblatt) % | -52.36 | |||||
| FCF Yield % | -20.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CRDF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cardiff Oncology Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.684 | ||
| EPS (TTM) ($) | -0.94 | ||
| Beta | 1.31 | ||
| 3-Year Sharpe Ratio | 0.47 | ||
| 3-Year Sortino Ratio | 1.26 | ||
| Volatility % | 92.99 | ||
| 14-Day RSI | 28.12 | ||
| 14-Day ATR ($) | 0.259981 | ||
| 20-Day SMA ($) | 3.57 | ||
| 12-1 Month Momentum % | -34.13 | ||
| 52-Week Range ($) | 2.01 - 6.35 | ||
| Shares Outstanding (Mil) | 66.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cardiff Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cardiff Oncology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cardiff Oncology Inc Frequently Asked Questions
What is Cardiff Oncology Inc(CRDF)'s stock price today?
The current price of CRDF is $2.75. The 52 week high of CRDF is $6.35 and 52 week low is $2.01.
When is next earnings date of Cardiff Oncology Inc(CRDF)?
The next earnings date of Cardiff Oncology Inc(CRDF) is 2025-05-02 Est..
Does Cardiff Oncology Inc(CRDF) pay dividends? If so, how much?
Cardiff Oncology Inc(CRDF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers